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Abstract 
Background: 
Several studies have evaluated short-term neonatal outcome in infants with congenital lung lesions (CLL) but clinical 
course and lung function on the longer term have not yet been documented. We hypothesized that clinical course and 
lung function would be affected negatively by surgical resection.  
Objective:  
To evaluate respiratory symptoms and lung function longitudinally in the first year of life in infants with CLL and analyse 
differences herein between infants managed by observation only and infants whose affected lung parts were resected.  
Methods 
In 30 patients with CLL we evaluated respiratory symptoms and lung function at 6 and 12 months. Functional residual 
capacity (FRCp) and maximal expiratory flow at functional residual capacity (V’maxFRC) were measured with body 
plethysmography. SD-scores were calculated for V’maxFRC. 
Results 
Prevalence of respiratory symptoms did not differ between the groups. Mean FRCp (95% CI) was 25.3 (23.3-27.3) in the 
group managed by observation vs. 27.3 (25.1-29.6) in the group managed by surgery (p=0.149). Mean (95%CI) SDS 
V’maxFRC was -1.45 (-1.84 to -1.06) vs. -1.41 (-1.90 to -0.91) (p=0.892). Lung function did not change significantly over 
the six month period.  
Conclusion 
Surgical resection did not seem to have negatively affected clinical course and lung function. We recommend pulmonary 
follow-up of all CLL patients into adulthood to further identify any long term effects of CLL and observation or surgery.  
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Introduction 
Congenital malformations of the lung are rare with a reported estimate prevalence of one in 11.000-35.000 pregnancies 
and vary widely in their presentation and severity [1-3]. Advances in antenatal diagnostic techniques have improved the 
detection and characterisation of congenital lung lesions (CLL) [4]. The differential diagnosis of lung lesion includes 
congenital cystic adenomatoid malformation (CCAM), bronchopulmonary sequestration (BPS), bronchogenic cyst (BC) 
and congenital lobar emphysema (CLE). CCAMs are characterised by hamartomous growth of terminal respiratory 
structures deriving their blood supply from the pulmonary vasculature. BPSs are masses of non-functioning lung tissue, 
either in intralobar or extralobar form. BCs result from abnormal budding of the foregut, are usually unilocular, mostly 
located in the mediastinum and do not communicate with the airway [5]. CLE is a term used to describe a distended 
hyperlucent lobe, usually the left upper or right middle lobe, perhaps resulting from transient bronchial obstruction in utero 
[6].   
Natural courses of CLL in utero from severe hydrops to total regression have been observed [7]. In the perinatal period, 
air trapping within the cystic component of CCAM can result in life-threatening respiratory distress requiring immediate 
surgical intervention. Later in life, communication of the cysts with the airways can result in recurrent pneumonia for 
which surgical resection of the affected lung part(s) is indicated. Controversy remains whether asymptomatic lesions 
should be resected. Some centers prefer elective resection at 3-6 months to reduce the risk of infection [1]; others prefer 
observation only because asymptomatic lesions may regress spontaneously [8-9].  
Several studies evaluated short-term neonatal outcome but to our knowledge, lung function in the first year of life has not 
yet been documented. We hypothesized that clinical course and lung function parameters would be negatively affected 
by surgical resection. We report a prospective study in infants with CLL in which we established the respiratory morbidity 
at 6 and 12 months of life and analysed differences between infants with asymptomatic lesions, managed by observation, 
and those whose affected lung part(s) were resected. We also studied possible associations between clinical 
characteristics and lung function parameters.  
  
 
Methods 
Detailed information on methods is available online. We recorded demographic and clinical data of all CLL patients born 
in our centre between May 2005 and September 2010. We distinguished 2 groups: an observation group of 
asymptomatic infants and a surgical group whose affected lung (parts) were resected because of respiratory distress. 
The study was part of a routine follow-up program for CLL patients in which lung function, growth and developmental 
parameters are regularly assessed until 18 years [10-11]. The Medical Ethical Review Board Erasmus MC stated that 
“the Medical Research in Human Subjects Act does not apply to this research proposal, since subjects are not being 
submitted to any handling, nor are there rules of human behaviour being imposed”. Therefore approval was waived. All 
parents were informed and provided permission to use the data for research purposes.  
 
 
Respiratory morbidity and physical growth  
The infants were physically examined at the ages of 6 and 12 months. Examination included anthropometry and 
pulmonary auscultation. Respiratory rate (RR) was measured during lung function assessment. Clinical data on 
respiratory morbidity were recorded at both visits.  
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Infant lung function tests 
Infant lung function tests were done as described previously at the ages of 6 and 12 months (corrected for prematurity), if 
children were clinically stable [12]. Plethysmographic functional residual capacity (FRCp;mL/kg) was the primary outcome 
measure. Secondary outcome measures were the following: the standard deviation score (SDS) of forced expiratory flow 
at FRCp (V’maxFRC), respiratory symptoms, and anthropometric SDS.  
 
Data analysis 
Group comparisons were made with Mann Whitney U tests. Repeated measurements ANOVA served to evaluate lung 
function and growth parameters. The influence of clinical parameters on lung function was investigated with Univariate 
Mixed Models. For lung function and growth parameters, SDS <-1.96 (2.5th percentile of reference population) was 
considered abnormally low. The significance level was set at p < 0.05.  
 
 
Results 
Between May 2005 and December 2010, 55 of 57 newborns with a CLL survived (96%). For logistic reasons the 
survivors were gradually included in the follow-up program. Seventeen (31%) patients included after the first year of life 
were excluded from this study. Two other, asymptomatic, patients had serious neurological co-morbidity (1 with a 
chromosomal anomaly, 1 with Filamin A deficiency) as contraindication for lung function testing. Parents of 5 patients 
refused follow-up. One patient was awake during the first measurement and suffered from a RTI at the second occasion. 
Eventually, 30 of the 55 eligible patients (55%) participated in the follow-up program. 
Participants’ birth weight was significantly lower than that of the non-participants (median 2930 (1650-4200) g versus 
median 3580 (2450-4505) g; p=0.013). Other perinatal characteristics did not significantly differ between participants and 
non-participants (data not shown). Fifteen participants were measured at both time-points, 5 at 6 months only and 10 at 
12 months only (Figure online). Reasons for not completing both measurements were delayed inclusion (n=7), RTI (n=3), 
being awake (n=2), and logistic reasons (n=3). Clinical characteristics of participants are shown in Table 1. In 23/30 
patients (77%) the lung lesion had been identified by antenatal ultrasound scan. Thirteen (43%) developed respiratory 
symptoms and underwent resection at a median age of 3 weeks (range 0-39 weeks): lobectomy n=8; pneumonectomy 
n=2 (one needed treatment with veno-arterial extracorporeal membrane oxygenation); non-anatomical resection n=3. All 
patients were ventilated post-operatively; two were extubated on the day of surgery. Seven patients in the surgical group 
had been diagnosed antenatally: CCAM in 6 and congenital diaphragmatic hernia in 1. Postoperatively, the diagnosis 
CCAM was confirmed in 5 cases. One patient appeared to have a bronchopulmonary sequester. The other six patients in 
the surgical group were diagnosed postnatally. In five cases this diagnosis was confirmed by histology (1 CLE, 1 BC, 2 
BPS and 1 CCAM). In one patient an eventration of the diaphragm was suspected which during surgery and on histology 
appeared to be a broncho-pulmonary sequestration. Until now, all asymptomatic patients remained without symptoms. 
One underwent embolisation of the supplying artery of an extralobar bronchopulmonary sequestration at the age of 3.4 
years due to cardiac insufficiency. No malignancies have been observed histologically 
 
Respiratory morbidity and physical growth 
All 13 patients in the surgical group suffered from respiratory distress. Prevalences of respiratory symptoms did not 
significantly differ between the observation and surgical groups at 6 and 12 months (Table 2). Overall, significantly more 
therapeutic courses of antibiotics had been prescribed between 0-6 months than between 6-12 months (p=0.018). This 
difference did not reach statistical significance in the subgroups separately. Number of courses of antibiotics for RTI or 
respiratory symptoms did not differ between these two periods (Table 2).  
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There were no significant differences in SDS weight and SDS height between both groups. Overall, SDS weight at 12 
months was significantly below normal (p=0.037, Table 2).  
 
Infant lung function tests  
The median postnatal age at the two respective time points was 30 weeks (range 23-40 weeks, n= 20) and 54 weeks 
(range 49-72 weeks, n=25). Reliable FRCp measurements were obtained in 20 and 24 patients at 6 and 12 months 
respectively. Reliable V’maxFRC measurements were obtained in 19 and 25 patients at 6 and 12 months respectively. 
Results are shown in Table 1, Figures 1 and 2. FRCp and SDS V’maxFRC did not significantly differ between the 
observation and surgical group (p=0.796 and p=0.553 respectively). Mean (95%CI) FRCp was 25.3 (23.3-27.3) in the 
observation group vs. 27.3 (25.1-29.6) in the surgical group (p=0.149; mean (95%CI) SDS V’maxFRC was -1.45 (-1.84 to -
1.06) vs. -1.41 (-1.90 to -0.91) (p=0.892) and did not change significantly over time. All FRCp values were >13 mL/kg. 
Fifty percent of FRCp measurements were >26 mL/kg; i.e. in 13/26 (50%) patients in the observational group and 9/18 
(50%) patients in the surgical group. Mean SDS V’maxFRC was below normal at both time points in both groups. In the 
observational group 8/26 patients (31%) and 7/18 (39%) surgical patients had a SDS V’maxFRC <-1.96. 
 
Associations between lung function parameters and clinical characteristics 
We found no significant associations between FRCp and SDS V’maxFRC and gestational age, birth weight, log duration of 
ventilation, log duration of supplemental oxygen and observation or surgery at both time points.  
 
Discussion 
To our knowledge this is the first longitudinal study that evaluated lung function and respiratory morbidity in the first year 
of life in infants with a CLL. In contrast to our hypothesis, both FRCp and V’maxFRC did not differ between the two 
subgroups. FRCp values were in the upper or above normal range without a significant change from 6 to 12 months. SDS 
V’maxFRC was significantly below normal at 6 and 12 months without a significant change from 6 to 12 months. We found 
no significant associations between clinical characteristics and lung function parameters.  
 
Several studies on CLL describe antenatal observations and perinatal outcome. Malignant transformation was described 
but this issue remains controversial [3]. In our surgical group, no malignancies were observed. The management of 
initially asymptomatic lesions deserves attention because complications may arise like pneumonia, pneumothorax, 
hemoptysis and hemothorax [3]. Some centres recommend early surgical intervention to prevent these complications; 
this would also stimulate compensatory lung growth [1,13-14]. Marshall and colleagues reported that elective resection in 
asymptomatic patients was associated with shorter hospital stay and a trend towards lower major complication rates and 
overall decreased medical costs. The sample size however was too small to have statistical power [15]. Observational 
management may be warranted because asymptomatic lesions may remain asymptomatic or regress spontaneously. In 
the present study we looked at outcome parameters beyond the perinatal period to justify a policy of observation in 
asymptomatic patients.  
 
Compensatory lung growth after extensive resection of lung tissue was described in several (animal) studies [16-18]. 
However, our results do not testify to compensatory lung growth during children’s first year of life. FRCp measurements 
were in the upper normal or above normal range in both groups and did not change significantly from 6 to 12 months. 
FRCp is considered to represent lung volume during quiet breathing. However, as we observed previously, FRCp seems a 
poor estimate of the volume of functional lung parenchyma in infants with CLL [12]. Enlarged, air filled spaces in the lung 
parenchyma cause hyperinflation, reflected by increased FRCp. Also, FRCp values did not significantly differ between the 
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observation and surgical groups. We speculate this is due to hyperinflation of the remaining lung tissue or to the 
presence of residual abnormal lung tissue.  
 
Airway patency as measured by V’maxFRC was significantly below normal at both 6 and 12 months, and to the same 
extent in both subgroups. We assume, therefore, that this may be a consequence of the anatomical anomaly itself and 
not of surgical treatment and/or the subsequent mechanical ventilation. The hyperinflated cystic, or in some cases more 
solid, lesions can compress the surrounding structures which can result in a mediastinal shift observable on a chest X-ray 
or CT scan [14]. In 2009, Keijzer et al. performed pulmonary function tests in 14 CLL children (mean age 10 years) who 
all had undergone lobectomy. Test results pointed at mild airflow obstruction in all, irrespective of surgery having been 
performed before or after the 2
nd
 year of life [19]. 
 
In our study, respiratory morbidity was not significantly different between both subgroups. Only few patients needed 
inhalation medication (11% and 3% at 6 and 12 months respectively) or hospital admission for RTI (7% and 3% at 6 and 
12 months respectively). In contrast with our initial hypothesis, clinical course was not influenced negatively by surgery. 
We conclude that resection of congenital cystic lung lesions in the first weeks of life is tolerated well.   
 
A limitation of our study is the heterogeneity in the types of CLL and the consequently small numbers per type. Four 
different types of CLL were included with CCAM and BPS as the largest groups. However, type of CLL seemed to be of 
lesser importance as this was not our primary research question. Repeated measurements could be obtained in only 
15/30 patients (50%). However, repeated measurements ANOVA may have reduced the chance of a type II error. 
Multicenter studies allowing for larger samples are recommendable. Another potential limitation is the lack of a healthy 
control group. Sedation of healthy infants for research purposes is not permitted in the Netherlands; therefore we had to 
use lung function reference values published by others. We expressed FRCp values in mL/kg as described previously. 
The normal range of FRCp is 13-26 mL/kg, mean 19.6, SD 3.4 [20]. Regarding V’maxFRC, we used references values  
based on a large representative population of healthy infants that others have used testing with similar equipment as we 
did [21]. Another potential limitation is the lack of measurements shortly after birth or preoperatively. Five symptomatic 
patients needed respiratory support for respiratory distress shortly after birth. Our institution is not equipped for infant 
lung function testing in these circumstances. We recommend to use gas mixing techniques – which can be applied 
shortly after birth – to evaluate homogeneity of ventilation longitudinally in unsedated infants not on ventilatory support 
[22].  
 
In conclusion, we found no significant differences in respiratory morbidity and infant lung function parameters between 
the observation and surgical groups. However, we assume that FRCp is not suitable to assess possible compensatory 
lung growth in the first year of life after resection of lung part(s). The natural course of antenatally detected lung lesions 
could well be documented by standardized serial prenatal evaluation of the dimensions of lesion(s), routine assessment 
of the mediastinal shift together with postnatal imaging of the pulmonary vasculature at set moments in the first months of 
life. We recommend prolonged pulmonary follow-up of lung structure and function. 
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Table 1: Patient characteristics 
 
Variables   Total    Observation  Surgical  between  
       group    group    groups p 
 
N    30   17   13 
Males    21 (70)   13 (76)   8 (62)   0.385 
Gestational age (wks)  39.1 (38.0-41.0) 39.6 (37.1-41.6) 40.0 (34.7-41.7) 0.950  
Birth weight (grams)  3490 (3000-4505) 3585 (2450-4200) 3730 (2925-4505) 0.601 
Type lung lesion            0.887 
 CCAM   17 (57)   10 (59)   7 (54) 
 BPS   9 (30)   5 (29)   4 (31) 
 CLE   3 (10)   2 (12)   1 (8) 
 BC   1 (3)   0   1 (8) 
Duration ventilation (days) 0 (0-40)   0 (0-10)   2 (0-40)   <0.001 
 Conventional  0 (0-38)   0 (0-10)   2 (0-38)   <0.001 
 HFO   0 (0-11)   0   0 (0-11)     0.016 
Duration oxygen supply (days) 4 (0-42)   0 (0-10)   5 (0-42)   <0.001 
 
 
 
 
Table 1: CCAM: congenital cystic adenomatoid malformation, BPS: bronchopulmonary sequestration, BC: bronchogenic 
cyst, CLE: congenital lobar emphysema. HFO: high frequency oscillatory ventilation. P values are given for the 
differences between patients in the observation and surgical groups. Data demonstrated as number (%), median (range) 
or mean (SD) where appropriate. One asymptomatic CCAM patient had a laryngeal cyst causing upper airway 
compression, after resection of this specific lesion 10 days of mechanical ventilation were necessary.  
* significantly below normal (SDS=0), one sample t-test was used.  
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Table 2: Respiratory symptoms, growth and lung function at 6 and 12 months 
 
 
Age     6 mos     12 mos    
Resection   No  Yes   No  Yes  
 
RTI with AB treatment    
 None (n, %)  9/17 (53)  6/13 (46)   13/17 (76) 12/13 (92) 
 1 (n, %)  6/17 (35)  3/13 (23)   3/17 (18)  1/13 (8)  
 2 (n, %)  1/17 (6)  0   0  0 
 3 (n, %)  0  1/13 (8)   0  0 
 
Inhalation medication   
 No (n, %)  16/17 (94) 9/13 (69)   17/17 (100) 12/13 (92) 
 Yes (n, %)  1/17 (6)  2/13 (15)   0  1/13 (8) 
 
Admitted for RTI    
 No (n, %)  17/17  11/13 (85)  17/17  12/13 (92) 
 Yes (n, %)  0  2/13 (15)   0  1/13 (8) 
 
Auscultatory findings   
 Normal (n, %)  16/17 (94) 9/13 (69)   16/17 (94) 12/13 (92) 
 Wheezing (n, %)  0  1/13 (8)   1/17 (6)  1/13 (8) 
 
SDS height   0.45 (-0.13/1.03) 0.44 (0.09/0.98)  0.26 (-0.30/0.81) -0.88 (-0.62/0.44)   
SDS weight    0 (-0.51/0.50) -0.64 (-1.49/0.21)  -0.51 (-1.02/-0.01) -0.49 (-1.19/0.20) 
FRCp, mL/kg   25.5 (23.2/27.7) 25.6 (22.4/28.7)  26.9 (24.5/29.3) 26.6 (23.7/29.5) 
VmaxFRC, SDS   -1.42 (-1.68/-1.16) -1.41 (-2.48/-0.33)  -1.63 (-2.20/-1.06) -1.46 (-2.34/-0.58) 
RR, breaths/min   33 (31/37) 39 (32/45)  30 (28/33) 30 (27/33)   
 
Table 2: Respiratory symptoms: n= number of respiratory tract infections (RTI) in the past 6 months requiring treatment 
with antibiotics (AB). SDS weight height are expressed as mean (SD). Lung function: FRCp: functional residual capacity. 
VmaxFRC:  maximal expiratory flow at functional residual capacity. RR: respiratory rate. * p< 0.001 below the reference 
value (SDS = 0). Mean (95% CI) values from analysis of variance are shown. 
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Figure legends 
 
Flowchart (online) 
 
Figure 1: FRCp in observation and surgical group. 
FRCp (mL/kg) at 6 and 12 months (observation group; Figure 1a, surgical group 2; Figure 1b). The range of normal 
values (beween 13 and 26 mL/kg)  is indicated by dotted horizontal lines.  
Open circles represent CCAM: congenital cystic adenomatoid malformation, open squares represent BPS: 
bronchopulmonary sequestration, closed triangles represent CLE: congenital lobar emphysema, open diamonds 
represent BC: bronchogenic cyst. 
 
Figure 2: V’maxFRC in observation and surgical group. 
Standard deviation score (SDS) VmaxFRC at 6 and 12 months (observation group; Figure 2a, surgical group: Figure 2b).  
Open circles represent CCAM: congenital cystic adenomatoid malformation, open squares represent BPS: 
bronchopulmonary sequestration, closed triangles represent CLE: congenital lobar emphysema, open diamonds 
represent BC: bronchogenic cyst. 
Online Figure 
 
May 2005-December 2010:
57 neonates with CLL
27 non-participants:
2 deceased
2 co-morbidity
17 included > age 1 year
5 parental refusal
1 no lung function
30 participants:
Lung function 6 mos       : 5
12 mos     : 10
6+12 mos : 15
CCAM  : 16 (59%)
BPS      : 5 (19%)
CLE       : 2 (7%)
BC         : 3 (11%)
CCAM/CLE : 1 (4%)
CCAM : 17 (57%)
BPS    : 9 (30%)
CLE     : 3 (10%)
BC       : 1 (3%) 
Antenatal diagnosis : 23 (77%)
Resection:  13 (43%)
Antenatal diagnosis: 20 (74%)
Resection: 8 (30%)
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Online supplement 
 
Methods 
 
Of all CLL patients born in our centre between May 2005 and September 2010 we recorded data on antenatal ultrasound, 
gestational age, birth weight, gender, type of lung anomaly, duration of post-operative ventilation and supplemental 
oxygen. In the group of infants that underwent resection of the affected lung part(s), the surgical group, surgical 
procedure (lobectomy, pneumonectomy or non-anatomical resection) was recorded. Indications for surgery in our 
institution are respiratory distress with persistent need for oxygen and/or mechanical ventilation due to the presence of 
the congenital lung lesion. Another criterion for surgery is recurrent infection in the affected lung part(s). Asymptomatic 
infants, the observation group, were observed only.   
The study was part of a routine follow-up program for CLL patients in which lung function, growth and developmental 
parameters are regularly assessed until 18 years of age [1-2]. At 6 and 12 months of age they visited our outpatient clinic 
and lung function and growth amongst other parameters were assessed. The Medical Ethical Review Board Erasmus MC 
stated that “the Medical Research in Human Subjects Act does not apply to this research proposal, since subjects are not 
being submitted to any handling, nor are there rules of human behaviour being imposed”. Therefore approval was 
waived. All parents were informed and provided permission to use the data for research purposes. Lung function data 
were evaluated at the end of 2011.   
 
Respiratory morbidity and physical growth  
The infants were physically examined at the ages of 6 and 12 months. Examination included anthropometry and 
pulmonary auscultation. Respiratory rate (RR) was measured during lung function assessment. The occurrence of 
doctor-diagnosed respiratory tract infections requiring treatment with antibiotics and/or hospital admission in the previous 
6 months, and the use of inhalation medication were assessed by questionnaires and from the medical records of our 
hospital at both time points. Dutch population data served as reference values for physical growth [3]. 
 
Infant lung function tests 
Infant lung function tests were done at the ages of  6 and 12 months (corrected for prematurity), when children were 
clinically stable. Infants were sedated with chloral hydrate (50-75 mg/kg). Functional residual capacity (FRCp) was 
measured by whole body plethysmography (Masterscreen Babybody, Viasys, Hochberg, Germany) as described 
previously [4]. The earlier reference equations to compute FRCp into SD-scores are perhaps not entirely appropriate for 
data obtained with the newer equipment. The use of FRCp in mL/kg is acceptable in the neonatal period, as the 
regression of FRCp on weight is relatively linear and passes close to the origin. Until new reference data are available, we 
need to interpret results cautiously. The normal range of FRCp, suggested by Hülskamp et al, is 13-26 ml/kg, mean 19.6, 
SD 3.4 [5]. Forced expiratory flow at FRCp (V’maxFRC), a measure of airway patency and compressibility, was determined 
by the end-tidal rapid thoracoabdominal compression technique (Masterscreen Babybody, Viasys, Hochberg, Germany). 
Regarding V’maxFRC, we used the references values provided by Hoo and colleagues, which are based on a large 
representative population of healthy infants and have been used by others using similar equipment as we did [6]. 
FRCp (mL/kg) was the primary outcome measure. SDS VmaxFRC, respiratory symptoms and anthropometric SDS were the 
secondary outcome measures. All equipment and procedures complied with the guidelines of the ERS/ATS [7]. 
Adherence to these guidelines ensures an acceptable degree of precision and reproducibility. 
 
 
 2 
Data Analysis 
Group comparisons were made with Mann Whitney U tests. In a minority of patients, lung function was measured only at 
one of the two time points. Since repeated measurements ANOVA allows for missing data at one time point, mean (95% 
CI) FRCp, SDS V’maxFRC and SDS for weight and height were evaluated longitudinally using this method [8]. The 
following parameters were entered as covariates in univariate Mixed Models to investigate their influence on lung function 
parameters: gestational age at birth, birth weight, duration of ventilation, duration of supplemental oxygen, and 
management – either observation or surgery. The durations of ventilation and supplemental oxygen were transformed 
logarithmically to reduce the effect of outlying values. 
All results are expressed as number (percentage), mean (SD, 95% CI) or median (range) where appropriate. 
The significance level was set at p < 0.05. SPSS 17.0 (Chicago, Illinois) was used for the analyses. 
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